

***In Vitro* Antiviral Screening Program**

The National Institute of Allergy and Infectious Diseases (NIAID) In Vitro Antiviral Screening Program supports screening systems for the assessment of the efficacy and toxicity of potential therapeutic approaches for important human viral infections. The main objective of this program is to facilitate the identification of antiviral agents with the potential for treatment of viral infections of public health importance, including those for newly emerging infections, and those that are not a high priority for the pharmaceutical industry. The six

principal viral categories covered under this program include:

- Herpesviruses (HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-8);
- Respiratory viruses (Flu A&B, RSV, PIV, Measles, Rhino, Adeno, SARS);
- Hepatitis B virus, Hepatitis C virus;
- Orthopoxviruses (Vaccinia, Cowpox);
- Papillomaviruses, BK virus; and
- Biodefense: VEE, Punta Toro, Pichinde, Yellow fever, West Nile, Dengue.

To obtain more information, please visit the program's website at <http://www.niaid.nih.gov/dmid/viral/>. For more information about other NIAID biodefense research resources, please go to www.niaid.nih.gov/biodefense.

N I A I D B I O D E F E N S E R E S E A R C H

NIH Publication No. 04-5499
March 2004

